Department of Internal Medicine, Hatyai Hospital, Songkhla, Thailand.
Division of Gastroenterology, Department of Internal Medicine, Hatyai Hospital, Songkhla, 90110, Thailand.
Indian J Gastroenterol. 2022 Aug;41(4):352-361. doi: 10.1007/s12664-021-01227-y. Epub 2022 Aug 27.
To evaluate the factors influencing the achievement of a sustained complete response (CR) and overall survival (OS) in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE).
We retrospectively reviewed the records of HCC patients who underwent TACE as the first modality of treatment between 2014 and 2019. We investigated the factors affecting sustained CR (no recurrence within 6 months) and OS (time from diagnosis until either death or last follow-up).
The study enrolled 161 patients; 159 (98.8%) had cirrhosis. Post-TACE, 19.9% (32/161) achieved sustained CR. In the multivariate analysis, a tumor size < 5 cm was a positive factor for achieving sustained CR (odds ratio, 5.012; p = 0.006). In the proportional hazards model, the factors associated with decreased survival included alcohol-related liver disease (hazards ratio [HR] 1.683; p = 0.036), presence of symptoms (HR 1.816; p = 0.005) and portal hypertension (HR 1.608; p = 0.038) at initial diagnosis, serum alpha-fetoprotein (AFP) > 100 ng/mL (HR 2.082; p < 0.001), and higher Child-Pugh classification (HR 1.1.639; p = 0.024). Achievement of sustained CR (HR, 0.355; p = 0.002) was independently associated with increased survival.
The tumor size was a predictive factor for sustained CR. Alcohol-related liver disease, presence of symptoms and portal hypertension at initial diagnosis, elevated serum AFP, liver reserve status, and achieved sustained CR were independent factors affecting survival. We demonstrated the effect of alcohol-related liver disease on survival after TACE. Our results will aid physicians in the management and prognostication of HCC.
评估影响肝细胞癌(HCC)患者经肝动脉化疗栓塞术(TACE)治疗后持续完全缓解(CR)和总生存(OS)的因素。
我们回顾性分析了 2014 年至 2019 年间接受 TACE 作为一线治疗的 HCC 患者的病历。我们研究了影响持续 CR(6 个月内无复发)和 OS(从诊断到死亡或最后一次随访的时间)的因素。
本研究共纳入 161 例患者;159 例(98.8%)有肝硬化。TACE 后,19.9%(32/161)达到持续 CR。多因素分析显示,肿瘤直径<5cm 是达到持续 CR 的有利因素(优势比,5.012;p=0.006)。在比例风险模型中,与生存时间缩短相关的因素包括酒精性肝病(风险比[HR]1.683;p=0.036)、有症状(HR 1.816;p=0.005)和初诊时存在门脉高压(HR 1.608;p=0.038)、血清甲胎蛋白(AFP)>100ng/mL(HR 2.082;p<0.001)和较高的 Child-Pugh 分级(HR 1.1.639;p=0.024)。达到持续 CR(HR,0.355;p=0.002)与生存时间延长独立相关。
肿瘤大小是持续 CR 的预测因素。初诊时的酒精性肝病、有症状和门脉高压、血清 AFP 升高、肝脏储备功能和达到持续 CR 是影响生存的独立因素。我们证明了酒精性肝病对 TACE 后生存的影响。我们的结果将有助于医生对 HCC 的管理和预后判断。